Page 252 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 252
Viral Hepatitis: Hepatitis C - Clinical (Therapy)
P0766 EPIDEMIOLOGY OF VIRAL RESISTANCE IN GENOTYPE
1 INFECTED PATIENTS AT APPROVAL OF IFN-FREE DAA
COMBINATION THERAPY OF CHRONIC HEPATITIS C IN
GERMANY
Harald Farnik*, Johannes Vermehren, Simone Susser, Julia Dietz,
Dany Perner, Caterina Berkowski, Stefan Zeuzem, Christoph Sarrazin,
Germany
P0767 CLINICAL UTILITY OF HEPATITIS C VIRUS CORE ANTIGEN
TESTING IN THE MONITORING OF TREATMENT NAÏVE
NON-CIRRHOTIC PATIENTS RECEIVING AN ALL-ORAL,
INTERFERON-FREE REGIMEN
Gavin Cloherty*, Kevin Cheng, Stephane Chevaliez, Heiner Wedemeyer,
Christoph Sarrazin, Jordan Feld, Benjamin Maasoumy,
Christine Herman, John Hackett Jr., George Dawson,
Jean-Michel Pawlotsky, The United States
P0768 LATE MORTALITY IN TREATMENT-EXPERIENCED
CIRRHOTIC PATIENTS TREATED WITH TRIPLE THERAPY
ePOSTERS INCLUDING BOCEPREVIR OR TELAPREVIR IN A REAL-LIFE
COHORT–ANRS CO 20 CUPIC
Jean-Pierre Bronowicki*, Hélène Fontaine, Cécilie Dufour,
Fabien Zoulim, Dominique Larrey, Valérie Canva, Didier Samuel,
Thierry Poynard, Patrick Marcellin, Victor De Ledinghen,
Marc Bourlière, Laurent Alric, Jean-Pierre Zarski, Jean-Jacques Raabe,
Lawrence Serfaty, Sophie Metivier, Ghassan Riachi, Armand Abergel,
Véronique Loustaud-Ratti, Xavier Causse, Dominique Guyader,
Pierre-Henri Bernard, Pierre Attali, Vincent Di Martino, Patrice Cacoub,
Paul Cales, Albert Tran, Isabelle Rosa, Véronique Grando-Lemaire,
Isabelle Portal, Thong Dao, Damien Lucidarme, Thierry Fontanges,
Yohann Barthe, Jean-Michel Pawlotsky, Stanislas Pol, Fabrice Carrat,
Christophe Hezode, France
P0769 EFFICACY OF AN EIGHT-WEEK REGIMEN OF
GRAZOPREVIR PLUS ELBASVIR WITH AND WITHOUT
RIBAVIRIN IN TREATMENT-NAIVE, NONCIRRHOTIC HCV
GENOTYPE 1B INFECTION
John M. Vierling*, Marcelo Kugelmas, Eric Lawitz, Peggy Hwang,
Michael Robertson, Janice Wahl, Eliav Barr, Barbara Haber,
The United States
252 The International Liver Congress™ 2015 • ILC Programme
P0766 EPIDEMIOLOGY OF VIRAL RESISTANCE IN GENOTYPE
1 INFECTED PATIENTS AT APPROVAL OF IFN-FREE DAA
COMBINATION THERAPY OF CHRONIC HEPATITIS C IN
GERMANY
Harald Farnik*, Johannes Vermehren, Simone Susser, Julia Dietz,
Dany Perner, Caterina Berkowski, Stefan Zeuzem, Christoph Sarrazin,
Germany
P0767 CLINICAL UTILITY OF HEPATITIS C VIRUS CORE ANTIGEN
TESTING IN THE MONITORING OF TREATMENT NAÏVE
NON-CIRRHOTIC PATIENTS RECEIVING AN ALL-ORAL,
INTERFERON-FREE REGIMEN
Gavin Cloherty*, Kevin Cheng, Stephane Chevaliez, Heiner Wedemeyer,
Christoph Sarrazin, Jordan Feld, Benjamin Maasoumy,
Christine Herman, John Hackett Jr., George Dawson,
Jean-Michel Pawlotsky, The United States
P0768 LATE MORTALITY IN TREATMENT-EXPERIENCED
CIRRHOTIC PATIENTS TREATED WITH TRIPLE THERAPY
ePOSTERS INCLUDING BOCEPREVIR OR TELAPREVIR IN A REAL-LIFE
COHORT–ANRS CO 20 CUPIC
Jean-Pierre Bronowicki*, Hélène Fontaine, Cécilie Dufour,
Fabien Zoulim, Dominique Larrey, Valérie Canva, Didier Samuel,
Thierry Poynard, Patrick Marcellin, Victor De Ledinghen,
Marc Bourlière, Laurent Alric, Jean-Pierre Zarski, Jean-Jacques Raabe,
Lawrence Serfaty, Sophie Metivier, Ghassan Riachi, Armand Abergel,
Véronique Loustaud-Ratti, Xavier Causse, Dominique Guyader,
Pierre-Henri Bernard, Pierre Attali, Vincent Di Martino, Patrice Cacoub,
Paul Cales, Albert Tran, Isabelle Rosa, Véronique Grando-Lemaire,
Isabelle Portal, Thong Dao, Damien Lucidarme, Thierry Fontanges,
Yohann Barthe, Jean-Michel Pawlotsky, Stanislas Pol, Fabrice Carrat,
Christophe Hezode, France
P0769 EFFICACY OF AN EIGHT-WEEK REGIMEN OF
GRAZOPREVIR PLUS ELBASVIR WITH AND WITHOUT
RIBAVIRIN IN TREATMENT-NAIVE, NONCIRRHOTIC HCV
GENOTYPE 1B INFECTION
John M. Vierling*, Marcelo Kugelmas, Eric Lawitz, Peggy Hwang,
Michael Robertson, Janice Wahl, Eliav Barr, Barbara Haber,
The United States
252 The International Liver Congress™ 2015 • ILC Programme
